USE OF COST-CONSEQUENCE MODELS IN MANAGED CARE

被引:0
|
作者
BLISSENBACH, HF [1 ]
机构
[1] DIVERSIFIED PHARMACEUT SERV,MINNEAPOLIS,MN
来源
PHARMACOTHERAPY | 1995年 / 15卷 / 05期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functioning effectively as a pharmacy benefit manager has been defined as purchasing the best product at the lowest possible cost. In the simplest terms, this means purchasing discounted drugs; in the most complex terms, it means managing drug use. However, if the entire medical picture were analyzed, use of more expensive drugs might actually lower total direct medical costs. Currently, formulary decisions are based on both therapeutic necessity and cost. The decision to administer one drug rather than another is directed by community practice patterns and the final price. The availability of information to demonstrate differences, if any, in total treatment costs between the two agents would considerably enhance therapeutic decision making and would guide treatment by an outcome-based drug formulary. The question that requires an answer is centered on the value equation: Value = outcomes/cost. Before paying more for drug A than for drug B, the payer will demand to see value. When available, direct and indirect cost information will be applied to position drugs appropriately in a drug formulary.
引用
收藏
页码:S59 / S61
页数:3
相关论文
共 50 条
  • [1] Care pathways for reduced fetal movements: A cost-consequence analysis
    Mcknoulty, Matthew J.
    Martin, Elizabeth K.
    [J]. AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2024,
  • [2] COST-CONSEQUENCE MODELS FOR VARICELLA-ZOSTER VIRUS-INFECTIONS
    PAUL, JE
    MAUSKOPF, JA
    BELL, L
    [J]. PHARMACOTHERAPY, 1995, 15 (05): : S49 - S58
  • [3] Cost-consequence analysis for the handmaster in the Netherlands
    Nuijten, MJ
    Engelfriet, P
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A151 - A151
  • [4] A cost-consequence analysis of a menu intervention in early childhood education and care
    Kurkela, Olli
    Virtanen, S. M.
    Erkkola, M.
    Saarinen, M.
    Niinisto, S.
    Raulio, S.
    Ahokas, I.
    Meinila, J.
    Forma, L.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2023, 33
  • [5] Cost-Consequence Analysis of Advanced Imaging in Acute Ischemic Stroke Care
    Boltyenkov, Artem T.
    Martinez, Gabriela
    Pandya, Ankur
    Katz, Jeffrey M.
    Wang, Jason J.
    Naidich, Jason J.
    Rula, Elizabeth
    Sanelli, Pina C.
    [J]. FRONTIERS IN NEUROLOGY, 2021, 12
  • [6] OVERVIEW OF COST-CONSEQUENCE MODELING IN OUTCOMES RESEARCH
    STERGACHIS, A
    [J]. PHARMACOTHERAPY, 1995, 15 (05): : S40 - S42
  • [7] A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis
    Jimenez-Morales, Alberto
    Caliz, Rafael
    Aceituno, Susana
    Prades, Miriam
    Blanch, Carles
    [J]. REUMATOLOGIA CLINICA, 2021, 17 (09): : 536 - 542
  • [8] A COST-CONSEQUENCE ANALYSIS OF HUMAN PAPILLOMAVIRUS VACCINATION IN ROMANIA
    Preda, A. L.
    Moise, M.
    Van Kriekinge, G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A631 - A631
  • [9] Psychological safety in the perioperative environment: a cost-consequence analysis
    Cladis, Franklyn P.
    Hudson, Mark
    Goh, Joel
    [J]. BMJ LEADER, 2024,
  • [10] A cost consequence on concomitant drug use during HCV therapy in managed care patients in the United States
    Le, TK
    Yu, H
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 748 - 749